Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001109 | 1.00 | KMT2A (0.41) | KMT2ACNR2MAPTPOLBMEN1 | |
| SCHEMBL19001148 | 0.82 | KMT2A (0.62) | KMT2AMAPTPOLBMEN1RXFP1 | |
| SCHEMBL19012601 | 0.82 | KMT2A (0.62) | KMT2AMAPTPOLBMEN1RXFP1 | |
| SCHEMBL20249350 | 0.81 | KMT2A (0.38) | KMT2ACHRNB2CHRNA4CHRNA7HTR3A | |
| SCHEMBL20249382 | 0.80 | CHRNA7 (0.38) | KMT2ACHRNB2CHRNA4CHRNA7HTR3A | |
| SCHEMBL20249344 | 0.78 | KMT2A (0.36) | KMT2ACHRNB2CHRNA4CHRNA7HTR3A | |
| SCHEMBL19001038 | 0.73 | CNR2 (0.41) | CNR2MAPTPOLBRXFP1 | |
| SCHEMBL19001253 | 0.73 | CNR2 (0.41) | CNR2MAPTPOLBRXFP1 | |
| SCHEMBL20249359 | 0.73 | TRPV1 (0.42) | CNR2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20249165 | 0.73 | TRPV1 (0.42) | CNR2CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | KMT2A 325/4885CNR2 879/4885MAPT 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.